Slide 1: Elevating the World's Wellbeing
Elevating the World’s Wellbeing January 2023 – June 2023 – Q2 2023 results presentation
Slide 2: Forward-looking statement
Forward-looking statement This presentation contains certain forward-looking statements and opinions. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for example, contain wording such as "beli
Slide 3: Agenda
Agenda Q2 in short Business updates Financial results Strategy and outlook Q&A Henrik Molin CEO & co-founder Charlotte Goodwin CFO Q1 Q2 Q3 Q4 3
Slide 4: Q2 in short
Q2 in short Q1 Q2 Q3 Q4 4
Slide 5: €1.9m Quarterly progress
We completed the quarter on a strong footing despite a challenging macroeconomic environment demonstrating the resilience of the Physitrack Group 33% 32% 25% Adjusted EBITDA YTD Q2 YTD 2023 Q2 YTD 2023 organic increased to revenue growth revenue growth €1.9m Quarterly progress - In this quarter we i
Slide 6: Business updates
Business updates Q1 Q2 Q2 Q3 Q3 Q4 6
Slide 7: Our two business lines positioned to capitalize on digital healthcare demand
Our two business lines have us well-positioned to capitalize on increasing digital healthcare demand and corporate wellbeing challenges Q@= Mental Wellbeing ‘Your Results rh nme hit eo End Dy AE— =| lt ! = ero = Lifecare Wellness Seamless and One platform, All ’ Efficient care areas of employee " So
Slide 8: Lifecare quarterly developments
Lifecare quarterly developments Q2 Highlights: 8% growth in license numbers within • Collective effort across the entire division to identify efficiencies and high margin revenue opportunities to optimise the cost base. Lifecare • Physicourses expanded its service offering by partnering with world r
Slide 9: Wellness quarterly developments
Wellness quarterly developments Revenue, Wellness segment Q2 Highlights: 1.6 1.4 • Division going from strength to strength with another quarter of continued 1.2 99% significant growth. 1.0 • Results of new Champion Health SDR/AE sales organisation coming to fruition and 0.8 driving this growth, inc
Slide 10: Financial Results
Financial Results Q1 Q2 Q2 Q3 Q3 Q4 10
Slide 11: Q2 Financial Highlights
Q 1 2 Q2 Financial Highlights 3 month revenue 3 Month EBITDA 23% 168% €3.8m (Q2 2022: €3.1m) €0.7m (Q1 2022: €0.3m) 6 month Operating cashflow 6 month organic revenue 32% 2% growth €1.2m (Q2 2022: €1.3m) 3 month adjusted EBITDA 3 month adjusted EBITDA margin 6% €1.0m (Q2 2022: €0.9m) 25% (Q2 2022: 3
Slide 12: Maintaining revenue growth
Q 1 2 Maintaining revenue growth In-line with medium term growth targets Group Revenue Lifecare revenue growth Wellness revenue growth 2.5 4.0 2.5 25% 9% 3.5 2.0 23% 2.0 3.0 2.5 1.5 1.5 2.0 1.0 1.0 1.5 66% 1.0 0.5 0.5 0.5 - - - Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q1 Q2 Q3 Q4
Slide 13: EBITDA: Continued strong growth
Q 1 2 EBITDA Continued strong growth 2.0 1.8 14% €0.5M 1.6 1.4 1.2 €1.9M €1.7M €1.4M €1.2M 170% €'million 1.0 0.8 0.6 0.4 €0.5m ADJUSTED EBITDA ADJUSTED EBITDA Margin 0.2 Margin 29% 25% - 6 MONTHS 2022 EBITDA Adjusting it ems* 6 MONTHS 2022 Adjusted 6 MONTHS 2023 EBITDA Adjusting it ems* 6 MONTHS 20
Slide 14: Adjusted EBITDA by division
Q 1 2 Adjusted EBITDA 4.0 EBITDA by division 3.5 3.0 0.9 48% 2.3 Q2 2023 4% 0.1 2.5 (0.5) 2.0 0.9 14% 1.5 1.0 51% 2.2 0.9 1.0 Q2 2022 -% (0.5) 0.5 0.9 0.7 - (1.0) (0.5) - 0.5 1.0 1.5 2.0 2.5 2022 ADJ EBITDA 2023 ADJ EBITDA Lifecare Wel lness Group Q1 Q2 Q3 Q4 14 Q1 Q2 Q3 Q3 Q4
Slide 15: Cashflow
Q 1 2 3.0 Cashflow Available liquidity €2.8m 2.5 (0.7) 2.0 (0.1) €2.1m undrawn on 1.5 1.9 facility 2.1 1.0 (1.7) - 0.5 0.6 2.7 0.7 - 1 Jan 2023 Opening Net Adjusted EBITDA Working capital Interest expense Purchase of intangibles Deferred consideration Adjusting it ems Drawdown of Fx 30 June 2023 Clo
Slide 16: Continued focus on Free-cash-flow
Q 1 2 Continued focus on Free-cash-flow - Q122 Q222 Q322 Q422 Q123 Q223 (0.2) (0.4) (0.6) (0.8) (1.0) (1.2) (1) Free cash flow is defined as net cash from operating activities, less purchase of intangible assets and property, plant and equipment and finance costs 16 Q1 Q2 Q3 Q3 Q4
Slide 17: Balance Sheet
Q 1 2 Balance Sheet Strong liquidity position despite deferred consideration payments in Q1 30 June 2023 30 June 2022 Euros '000 Goodwill, intangibles and PPE 35,997 37,575 Cash and cash equivalents 673 4,118 Borrowings (3,694) - Trade and other receivables 3,335 2,827 Trade and other payables (2,09
Slide 18: Strategy and outlook
Strategy and outlook Q1 Q2 Q2 Q3 Q3 Q4 18
Slide 19: Our unique value proposition
Our unique value proposition Holistic offering, powered by top-of-the-line tech True product market fit Prices in relation to the market rather than growth expectations Catering to consumer trends Improved patient outcomes, through more personalized, data-driven care Positioned to capitalize on grow
Slide 20: How it all comes together - investing in Physitrack
How it all comes together - investing in Physitrack Market outlook and position Focus Areas High-reaching financial goals Top-line growth Growing market supported 1. Market growth by underlying macro dynamics Physitrack aims to achieve annual organic sales growth trends exceeding 30% in the medium t
Slide 21: Q&A
Q&A Q1 Q2 Q2 Q3 Q3 Q4 21